Aramon Neuro-Medical

Company Overview

Snapshot

Founded in January 2013, Aramon Neuro-Medical operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a new drug formulation for Parkinson's patients.

Business overview

Aramon Neuro-Medical is a biotechnology company focused on developing a novel drug formulation administered with a medical device for Parkinson's disease patients who are resistant to oral dopamine treatment. Its core technology involves a short-acting dopamine compound suitable for continuous subcutaneous infusion, aiming to provide individualized treatment and avoid risks associated with current therapies like percutaneous enterogastrostomy or deep brain stimulation. The company operates within the pharmaceutical sector, addressing a significant unmet medical need in the field of Parkinson's disease.

Company Intelligence Q&A

What is Aramon Neuro-Medical's primary focus?

Aramon Neuro-Medical is developing a new drug formulation and medical device for severely ill Parkinson's patients who do not respond to oral dopamine treatment.

When was Aramon Neuro-Medical founded?

Aramon Neuro-Medical was founded in January 2013.

What is the current employee count for Aramon Neuro-Medical?

Aramon Neuro-Medical currently has 1–10 employees.

What is Aramon Neuro-Medical's current funding stage?

Aramon Neuro-Medical is currently in the Pre-Funding stage.

What market need does Aramon Neuro-Medical address?

Aramon Neuro-Medical addresses the unmet medical need for approximately 10% of Parkinson's patients who are resistant to oral dopamine treatment.